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Abstract
Background and Aims: Patients infected with genotype 2b hepatitis C virus (HCV) generally can achieve favorable
responses to pegylated-interferon plus ribavirin therapy (PEG-IFN/RBV). However, a proportion of patients show poorer
responses and the correlation between viral sequence variation and treatment outcome remains unclear.
Methods: The pretreatment complete open reading frame (ORF) sequences of genotype 2b HCV determined by direct
sequencing were investigated for correlation with the final outcome in a total of 60 patients.
Results: In this study group, 87.5% (14/16) of non-sustained virological response (non-SVR) patients (n=16) were relapsers.
Compared to sustained virological response (SVR) patients (n=44), non-SVR patients were older and could not achieve
prompt viral clearance after the therapy induction. Comparing each viral protein between the two groups, viral sequences
were more diverse in SVR patients and that diversity was found primarily in the E1, p7, and NS5A proteins. In searching for
specific viral regions associated with the final outcome, several regions in E2, p7, NS2, NS5A, and NS5B were extracted.
Among these regions, part of the interferon sensitivity determining region (ISDR) was included. In these regions, amino acid
substitutions were associated with the final outcome in an incremental manner, depending upon the number of
substitutions.
Conclusions: Viral sequences are more diverse in SVR patients than non-SVR patients receiving PEG-IFN/RBV therapy for
genotype-2b HCV infection. Through systematic comparison of viral sequences, several specific regions, including part of
the ISDR, were extracted as having significant correlation with the final outcome.
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Introduction
Worldwide, 180 million people are estimated to be infected with
hepatitis C virus (HCV), a major cause of chronic hepatitis, liver
cirrhosis, and hepatocellular carcinoma (HCC) [1]. In HCV-
infected patients with chronic hepatitis, treatment with interferon
(IFN)-based therapy can result in viral clearance as well as
biochemical and histological improvements [2]. In this IFN-based
therapy, HCV genotype is the most significant factor affecting
treatment responses [3,4].
In genotype 2b HCV infection, 80% of patients with high viral
titers can achieve a sustained virological response (SVR) to the
regimen of pegylated-interferon (PEG-IFN) plus ribavirin (RBV)
for 24 weeks [5,6]. This response is high considering that much
lower percentages of patients infected with other genotypes can
achieve SVR, especially with genotype 1 [1]. However, in other
words, 20% of patients infected with genotype 2b HCV still
cannot clear the virus and remain at risk of developing HCC. On
the other hand, although various studies have been undertaken to
clarify the factors contributing to the response to IFN-based
therapy in genotype 1 infection, it remains poorly understood
which patients with genotype 2b HCV infection will show
unfavorable responses. Recently, the significance of IL28B single
nucleotide polymorphisms (SNPs) in determining the response to
PEG-IFN/RBV therapy was demonstrated in genotype 1 HCV
infection [7,8]. However, the significance of IL28B SNPs was
rather weak in genotype 2 HCV infection [9].
In terms of the association between HCV sequence variation
and treatment responses, previous studies have reported that
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[11], NS5B [12], PKR-eIF2 phosphorylation homology domain
(PePHD) of E2 [13], and Core [14] correlate with the clinical
outcome of IFN-based therapy, including PEG-IFN/RBV therapy
for genotype 1b HCV infection. In the meantime, these viral
sequence studies have been controversial regarding their true
clinical importance, because the results of different studies were
not always coincident [15,16,17]. On this background, recent
studies trying to analyze the correlation of complete HCV open
reading frame diversity, clinical characteristics, and the response to
PEG-IFN/RBV therapy for genotype 1 HCV infection, in the
most comprehensive approach yet attempted, have clarified that
viral amino acid variation is associated with treatment responses,
with consideration of racial background [18,19]. In genotype 2
infection, however, only a few studies have investigated the
association of HCV sequence variation and treatment response
[20,21] and the clinical significance has been yet established. We
reported recently that variation of amino acid (aa) 110 in Core and
amino acids (aa) 2258–2308 in NS5A were significantly associated
with treatment outcome of the PEG-IFN/RBV therapy for
genotype 2a HCV infection, through the analysis of the complete
HCV ORFs in Japanese patients [22].
In this study, to assess comprehensively the influence of viral
sequence variation on the response to the PEG-IFN/RBV therapy
in genotype 2b HCV infection, we determined the complete
pretreatment HCV ORFs from Japanese patients and investigated
amino acid variation and its correlation with the response to
combination therapy with PEG-IFN plus RBV.
Methods
Patients
A total of 77 adult Japanese patients infected with genotype 2b
HCV, who received the combination therapy with PEG-IFN
Table 1. Baseline Characteristics of Studied Patients.
Characteristic SVR (n=44) non-SVR (n=16) P value
Gender (Male/Female) 26/18 9/7 NS
{
Age (yrs) 56 (22–72)
* 59 (30–80) 0.04
{
BMI 23.5 (16.6–30.3) 24.7 (18.5–31.7) NS
{
ALT (IU/l) 51 (19–380) 41 (17–390) NS
{
GGTP (IU/l) 36 (11–133) 40 (17–292) NS
{
T.Chol (mg/dl) 169 (119–225) 178 (145–217) NS
{
WBC (/ml) 4600 (2620–7200) 5080 (3270–8600) NS
{
Hb (g/dl) 14.2 (11.5–17.3) 14.6 (11.8–16.4) NS
{
Platelet (610
4/mm
3) 19 (7.1–31.8) 17.8 (8–36.7) NS
{
Fibrosis score (0–2/$3)
1 38/5 7/3 NS
{
HCV RNA (KIU/ml) 2050 (100–16000) 1800 (140–6300) NS
{
IFN dose ($80%/60–80%) 36/8 13/3 NS
{
Ribavirin dose
($80%/60–80%)
32/12 10/6 NS
{
RVR rate (%) 55.8 6.3 0.0008
{
EVR rate (%) 97.7 68.8 0.004
{
ETR rate (%) 100 87.5 NS
{
1: SVR : n=43, non-SVR : n=10.
*: median (range).
{: Fisher’s exact probability test.
{: Mann-Whitney’s U test.
doi:10.1371/journal.pone.0024514.t001
Figure 1. Phylogenetic analysis of the genotype-2b polypro-
tein sequences. In order to perform the phylogenetic analysis, we first
aligned all 60 HCV complete ORF amino acid sequences obtained from
the patients along with reference sequences (2b.HC-J8.D10988,
2.JP.MD2b9-2, and 2a.JP.JFH-1.AB047639), using the ClustalW program,
and constructed the phylogenetic tree using the Neighbor-Joining
method with MEGA version 4 software. Blue circles indicate SVR
patients and red circles indicate non-SVR patients.
doi:10.1371/journal.pone.0024514.g001
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(REBETOLH, Schering-Plough) between 2005 and 2009 at
University of Yamanashi, Tokyo Medical and Dental University,
and related institutions were first included in the study. They all
fulfilled following criteria: (1) negative for hepatitis B surface
antigen, (2) high viral load ($100 KIU/ml), (3) absence of
Figure 2. Number of amino acid substitutions per sample in the sustained virological responders (SVR) and the non-sustained
virological responders (non-SVR) group. The numbers of variations, relative to a population consensus, that were unique to either SVR or non-
SVR patients are shown for the complete open reading frame (ORF) (Fig. 1, left) and for each HCV protein (Fig. 1, right).
doi:10.1371/journal.pone.0024514.g002
Figure 3. Different amino acid usage at each viral amino acid position between the sustained virological responders (SVR) and the
non-sustained virological responders (non-SVR) patients. (a) Different amino acid usage at each viral amino acid position between the SVR
and the non-SVR patients was analyzed by Fisher’s exact probability test. The longitudinal axis shows the 2logP value. (b) Sequence alignment in the
Core region is demonstrated. Dashes indicate amino acids identical to the consensus sequence and substituted amino acids are shown by standard
single letter codes.
doi:10.1371/journal.pone.0024514.g003
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primary biliary cirrhosis, autoimmune liver disease, or alcoholic
liver disease, (5) free of co-infection with human immunodeficiency
virus. To clearly disclose the non-SVR viral characteristics, we
have considered only those patients who achieved total drug
administration of 60% or more for both PEG-IFN and RBV, with
the completion of the standard treatment duration. Moreover,
although we excluded patients with extended therapy to make the
studied population uniform, we have included non-SVR patients
with extended therapy to clarify the specific characteristics of non-
SVR patients, a minor population group. As a result, 17 patients
were excluded for the following reasons: 1 patient received
insufficient dose, 4 patients were discontinued from the therapy
within 12 weeks, and 12 SVR patients received extended therapy.
Finally, 60 patients were considered as eligible for the study.
During the combination therapy, blood samples were obtained at
least once every month before, during and after treatment and
were analyzed for blood count, ALT and HCV RNA levels. Liver
biopsy specimens were obtained from most of the patients. All
patients gave written informed consent to the study. The study was
approved by the ethics committees of University of Yamanashi,
Tokyo Medical and Dental University, and related institutions.
The therapy was performed according to the standard treatment
protocol of PEG-IFN/RBV therapy for Japanese patients
established by a hepatitis study group of the Ministry of Health,
Labour, and Welfare, Japan (PEG-IFNa-2b 1.5 mg/kg body
weight, once weekly subcutaneously, and RBV 600–800 mg daily
per os for 24 weeks).
Complete HCV-ORF Sequence Determination by Direct
Sequencing from Pretreatment Sera
HCV RNA was extracted from pretreatment serum samples by
the AGPC method using Isogen (Wako, Osaka, Japan) according
to the following protocol. Briefly, 150 ml of serum were mixed with
700 ml of Isogen, and an aqueous phase was extracted with 150 ml
of chloroform. RNA was precipitated with 600 ml of isopropanol
and with 2 ml of Glyco Blue (Ambion, Tokyo, Japan) as a carrier.
The purified RNA was washed once with ethanol and finally
dissolved in 15 ml of distilled water and stored at 270uC until use.
Complementary DNA was synthesized according to the
following protocol. 30 ml of the reverse transcription mixture were
adjusted to contain 3 ml of the RNA solution, 300 U of Superscript
Table 2. Variation at each Amino Acid Position and SVR rate.
E2
aa 404 non T
E2
aa 530 non T
NS5A
aa 2359 N
NS5B
aa 2631 non P
SVR rate 86.1%
(31*/36**, p=0.008)
87.9%
(29/33, p=0.008)
82%
(41/50, p=0.002)
94.7%
(18/19, p=0.012)
*SVR number in patients fulfilling the criteria.
**Number of patients fulfilling the criteria.
doi:10.1371/journal.pone.0024514.t002
Figure 4. Sliding window analysis. (a) Comparison of amino acid variation between the SVR and non-SVR patients across HCV ‘‘regions’’ using
sliding window analysis was performed. Viral regions affecting treatment outcome are shown as red areas. There are six hot areas: amino acid 400–
408 and 723–770 in the E2 region, amino acid 879–893 in the NS2 region and, amino acid 2045–2051, 2224–2242 and 2379–2405 in the NS5A region.
(b) Sequence alignment in the nonstructural (NS)5A around amino acids 2213 to 2274 is demonstrated. Dashes indicate amino acids identical to the
consensus sequence and substituted amino acids are shown by standard single letter codes.
doi:10.1371/journal.pone.0024514.g004
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according to the manufacturer’s instructions, 60 units of RNase
inhibitor (Promega Corp., Madison, WI), and 300 pg of random
primers (Invitrogen). The mixture was incubated at 37uC for
30 min. The HCV genome was amplified with 24 partially
overlapping primer (Table S6) sets, designed specifically for this
study, to perform two-step nested PCR. As previously reported, a
M13 forward primer (59-TGTAAAACGACGGCCAGT-39) and a
M13 reverse primer (59-CAGGAAACAGCTATGACC-39) were
attached to the 59 termini of the sense and antisense second-round
PCR primers, respectively, to facilitate direct sequencing. All
samples were initially denatured at 95uC for 7 min., followed by
40 cycles with denaturation at 95uC for 15 seconds, annealing at
55uC for 15 seconds, and extension at 72uC for 45 seconds with
BD Advantage
TM 2 PCR Enzyme System (BD Biosciences
Clontech, CA, USA). PCR amplicons were sequenced directly
by Big Dye Terminator Version 3.1 (ABI, Tokyo, Japan) with
universal M13 forward/M13 reverse primers using an ABI prism
3130 sequencer (ABI). The sequence files generated were
assembled using Vector NTI software (Invitrogen) and base-
calling errors were corrected following visual inspection of the
chromatogram. When several peaks were observed at the same
nucleotide position in the chromatogram, the highest chromato-
gram peak was read as the dominant nucleotide. In sequence
analysis, multiple sequence alignment was performed with
ClustalW, and the mean genetic distance was calculated using
the p-distance algorithm in the MEGA version 4 DNA software.
As a result, 60 genotype-2b HCV full open reading frame
sequences were determined. In Table S1, obtained GenBank
accession numbers for these sequences determined in this study are
listed.
Sliding Window Analysis
A sliding window analysis was introduced to search through
HCV amino acid ‘‘regions’’, rather than single amino acid
positions, related to the final outcome of PEG-IFN/RBV therapy.
Briefly, the total number of amino acid substitutions compared to
the consensus sequence within a given amino acid length were
counted at each amino acid position in each HCV sequence. The
consensus sequence was generated from these 60 patients. Then
the relation of substitution numbers and the final outcome was
compared statistically between the SVR and non-SVR groups by
Mann-Whitney’s U test for each amino acid position. In this study,
we changed the window length from 1 to 50 to search for those
HCV regions. To visualize the result, significantly lower p-values
were colored in red and non-significant p-values were colored in
green using Microsoft Excel software to generate a ‘‘heat map’’
appearance. In the present study, p-value of 1/300 or lower was
colored in the maximum red.
Statistical Analysis
Statistical differences in the parameters, including all available
patients’ demographic, biochemical, hematological, and virolog-
ical data such as sequence variation factors, were determined
between the various groups by Mann-Whitney’s U test for
numerical variables and Fisher’s exact probability test for
categorical variables. To evaluate the optimal threshold of
variations for SVR prediction, a receiver operating characteristic
curve was constructed and the area under the curve as well as the
sensitivity and specificity were calculated. Variables that achieved
statistical significance (p,0.05) in univariate analysis were entered
into multiple logistic regression analysis to identify significant
independent factors. We also calculated the odds ratios and 95%
confidence intervals. All p values of ,0.05 by the two-tailed test
were considered significant.
Results
Characteristics of the patients studied
The SVR rate of the patients analyzed was 75.9% (44/58) with
the standard therapy (two non-SVR patients received extended
therapy). The baseline characteristics of the patients classified
according to achievement of SVR are shown in Table 1. Rapid
virological response (RVR; undetectable serum HCV RNA within
4 weeks) and early virological response (EVR; undetectable serum
HCV RNA within 12 weeks) rates were significantly higher in
SVR patients (p=0.0008 and 0.004). In addition, patients with
non-SVR were older (p=0.04). Pretreatment HCV RNA titer,
which is known to affect the treatment outcome in genotype 1 and
2a HCV infection, did not differ significantly between two groups.
Achievement of RVR reached 42.4% when all patients were
included, and this rate was high compared to achievement of RVR
in patients with genotype 1b infection (,10%) observed in
Table 3. Number of Amino Acid Substitutions in each Region and SVR rate.
E2
aa 400–408
mutation $4
E2
aa 723–770
mutation $2
NS2
aa 879–893
mutation $2
NS5A
aa 2045–2051
absense of
mutation
NS5A
ISDR
(aa 2213–2248)
mutation $1
NS5A
aa 2224–2242
mutation $1
NS5A
aa 2379–2405
mutation $2
SVR rate 86.5% (32*/37**)
p=0.006
100% (18/18)
p=0.001
94.7% (18/19)
p=0.01
89.7% (35/39)
p=0.0002
86.1% (31/36)
p=0.008
90.9% (30/33)
p=0.001
90.9% (20/22)
p=0.03
*SVR number in patients fulfilling the criteria.
**Number of patients fulfilling the criteria.
doi:10.1371/journal.pone.0024514.t003
Table 4. Multivariate Logistic Regression Analysis.
Factor odds (95% CI) p value
Age 0.94 (0.85–1.04) 0.20
E2 aa 530 non T 4.33 (0.48–39.3) 0.19
NS5A aa 2359 N 3.22 (0.18–57.7) 0.43
NS5B 2631 non P 5.14 (0.29–91.2) 0.26
NS2 aa 879–893 mutations $2 9.77 (0.52–182) 0.13
NS5A aa 2045–2051 no mutations 4.46 (0.39–50.6) 0.23
NS5A aa 2224–2242 mutations $1 11.0 (1.13–107) 0.04
NS5A aa 2379–2405 mutations $1 7.03 (0.62–79.8) 0.12
To evaluate the optimal threshold of amino acid variations for SVR prediction in
each viral region extracted, a receiver operating characteristic curve was
constructed and the most optimal cut off value was determined for each
region.
doi:10.1371/journal.pone.0024514.t004
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response (EVR) rate was equally high in the SVR (97.7%) and
non-SVR (68.8%) groups. Interestingly, most of the non-SVR
patients (14/16, 87.5%) in genotype-2b HCV infection showed
end-of-treatment response (ETR; undetectable serum HCV RNA
at the end of therapy), demonstrating that the main cause of non-
SVR was relapse (reappearance of hepatitis C viremia during the
follow-up period after stopping therapy in patients with an ETR,
n=14), and not null response (detectable serum HCV RNA at the
end of therapy, n=2).
Phylogenetic analysis of SVR and non-SVR patients using
the complete HCV amino acid sequence
To determine the viral sequence characteristics in the SVR and
non-SVR groups, we first aligned all 60 HCV complete ORF amino
acid sequences obtained from the patients’ pretreatment sera along
Figure 5. Correlation between pretreatment HCV RNA levels and the number of substitutions in the NS5A region aa 2224 to 2242.
Spearman’s correlation coefficient by rank test is demonstrated.
doi:10.1371/journal.pone.0024514.g005
Table 5. Baseline Characteristics of patients with NS5A aa 2224–2242 variations none or 1#.
Characteristic Variation 1# (n=33) No variation (n=27) P value
Gender (Male/Female) 17/16 18/9 NS
{
Age (yrs) 57 (29–72)
* 57 (22–80) NS
{
ALT (IU/l) 72 (19–380) 47 (17–390) NS
{
Platelet (610
4/mm
3) 19.3 (7.1–31.8) 17.5 (10.4–36.7) NS
{
Fibrosis score (0–2/$3)
1 26/5 19/3 NS
{
HCV RNA (KIU/ml) 1600 (100–16000) 2450 (140–13000) NS
{
IFN dose ($80%/60–80%) 26/7 23/4 NS
{
Ribavirin dose ($80%/60–80%) 24/9 19/8 NS
{
RVR rate (%) 53.1 29.6 NS
{
EVR rate (%) 96.9 81.5 NS
{
SVR rate (%) 90.9 51.9 0.001
{
Replapse rate (%) 40.7 9.1 0.006
{
1:1 # : n=31, 0 : n=22.
*: median (range).
{: Fisher’s exact probability test.
{: Mann-Whitney’s U test.
doi:10.1371/journal.pone.0024514.t005
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2a.JP.JFH-1.AB047639 obtained from the Los Alamos HCV
Database as representative sequences for genotype 2b and genotype
2a HCV) and constructed a phylogenetic tree (Fig. 1). As
demonstrated in the tree, no evident clustering was apparent
according to the difference of responses.
Comparison of amino acid variation between the SVR
and non-SVR in the complete HCV polyprotein and each
HCV protein
Next, we compared amino acid variations that were unique,
relative to a population consensus, to either the SVR or non-SVR
patients for the complete HCV polyprotein and each HCV
protein. The number of amino acid variations in the sequences
from the SVR patients was significantly higher than in those from
the non-SVR patients, when the entire HCV polyprotein was
analyzed (Fig. 2, left). These differences were especially significant
in E1, p7 and NS5A (Fig. 2, right). This result demonstrated that
HCV sequences from patients with SVR comprised a heteroge-
neous population, while HCV sequences from patients with non-
SVR comprised a rather homogeneous population, indicating the
existence of unique non-responsive HCV sequences in those
regions in E1, p7, and NS5A.
Comparison of HCV sequence variation between the SVR
and non-SVR patients at each amino acid position
Each amino acid position in the HCV ORF was compared to
detect any differences between the SVR and non-SVR patients. In
Fig. 3a, differences in amino acid resides at each position are
shown as dots demonstrating 2logP values. As shown in Table 2,
four points were extracted: amino acid (aa) 404 in the E2 region
(p=0.008), aa 530 in the E2 region (p=0.008), aa 2359 in the
NS5A region (p=0.002) and aa 2631 in the NS5B region
(p=0.012). Among them, the residue at aa 2359 in the NS5A
region differed most frequently between the SVR and non-SVR
patients. Amino acids 4 and 110 in the Core region, residues that
have been reported to vary according to the virological responses
in genotype 2a infection [22,23], did not differ significantly in this
genotype 2b HCV study. Meanwhile, amino acids 70 and 91,
which have been reported to vary according to virological
response to PEG-IFN/RBV therapy in genotype 1b infection,
were conserved irrespective of the outcome (Fig. 3b).
Comparison of amino acid variation between the SVR
and non-SVR patients across HCV ‘‘regions’’ using sliding
window analysis
Fig. 4a and Table 3 shows the result of sliding window analysis.
This approach was used to detect differing HCV amino acid
‘‘regions’’, rather than single amino acid positions, between the
SVR and the non-SVR patients. According to the result, six
regions were associated with the final outcome (p-values less than
1/20): aa 400–408 in the E2 region (p=0.006), aa 723–770 in the
E2 and the N-terminus of p7 region (p=0.001), aa 879–893 in the
NS2 region (p=0.01), aa 2045–2051 in the NS5A region
(p=0.0002), aa 2224–2242 in the NS5A region (p=0.001) and
aa 2379–2405 in the NS5A region (p=0.03). Interestingly, aa
2224–2242 in the NS5A was located in the interferon sensitivity
determining region (ISDR). Fig. 4b shows the aligned sequences of
amino acids around 2213–2274 of HCV NS5A. Among these 6
regions, aa 723–770, aa 879–893, aa 2224–2242, and aa 2379–
2405 were correlated with the final outcome in an incremental
manner according to the number of substitutions in those regions
(Table S2, S3, S4, S5). The number of substitutions in the ISDR
was also correlated to the final outcome in an incremental step-up
manner (data not shown).
Multivariate analysis to detect independent predictive
factors contributing to the SVR
Next, multivariate analysis was undertaken to identify pretreat-
ment variables correlated with the final outcome. To evaluate the
optimal threshold of amino acid variations for SVR prediction in
each viral region extracted, a receiver operating characteristic curve
was constructed and the most optimal cut off value was determined
for each region. E2 aa404–408 was excluded from the analysis
b e c a u s ew ec o n s i d e r e dt h a tt h er e g i o nw a su n l i k e l yt ob et r u l y
associated to the outcome as it is located in the hypervariable region,
the region of the highest mutation rate in the HCV genomeas a result
of host’s immune attack. E2 aa 723–770 was excluded from the
analysis because all the patients above the cut-off value in the region
achieved SVR and an odds calculation was not possible. The ISDR
was also excluded because NS5A aa2224–2242 was completely
contained in the ISDR. In addition, variables of EVR and RVR were
excluded because they were post treatment variables. The multivar-
iate analysis revealed that only NS5A aa 2224–2242 (odds ratio 11.0,
p=0.039)wasfinallyidentifiedastheindependent variable predicting
the final outcome (Table 4).
Biological relevance of variation in NS5A in this study
group
Because NS5A aa 2224–2242 is located within the ISDR, for
which the amino acid substitution numbers have been reported to
be correlated with the HCV RNA titer in genotype 1 and 2a HCV
infection [13], we analyzed the relationship between amino acid
variations in that region and pretreatment HCV RNA titers.
Contrary to our expectation, no evident relationship was found
between variations in the NS5A region aa 2224–2242 and HCV
RNA titer (Fig. 5). On the other hand, as shown in Table 5,
although the initial viral responses (RVR or EVR) did not show
evident association with the amino acid variations in the region,
treatment relapse was significantly correlated with the amino acid
variations in the region. In addition to NS5A aa 2224–2242, there
was no evident relationship between HCV RNA level and
variations in the other regions found in this study (data not shown).
Discussion
In this study, we showed that genotype 2b HCV sequences from
Japanese patients who achieved SVR were more diverse than the
sequences from patients with non-SVR. The result that SVR
patients were more diverse in their HCV sequences than non-SVR
patients is in accordance with previous studies of genotype 1 HCV
infection, although the diverse viral genes varied according to
genotype [18,19]. We found that these diversities were primarily
found in E1, p7 and NS5A.
In systemic searching for singleamino acid positions or consecutive
amino acid regions in the HCV ORF associated with the treatment
outcome, several regions were extracted in E2, p7, NS2, NS5A and
NS5B. Among those identified regions, E2 aa 723–770, NS2 aa 879–
893, NS5A aa2224–2242, and NS5A aa2379–2405 were correlated
with the final outcome in an incremental manner according to the
number of amino acid substitutions. Specifically, the sequences of
those regions in non-SVR patients were almost homogeneous, while
the sequences of the region in SVR patients were significantly diverse
and multiple amino acid substitutions were found compared to the
consensus sequence. Interestingly, among those regions, aa 2224–
2242 was completely included in the ISDR, in which the number of
amino acid substitutions is known to show significant correlation with
HCV2b Sequences and PEG-IFN/RBV Response
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in genotype 2 [21,24].
In recent studies of genotype 1b infection, amino acid variation of
residues 70 and 91 in the Core were reported to be associated with
the treatment response to IFN-based therapy. The correlation of
amino acid variation in the Core (residues 4 and 110) with the
response to PEG-IFN/RBV therapy was also identified in genotype
2a infection [22,23]. In genotype 2b infection, however, we could
not find such associations between amino acid variation in the core
region and the response to PEG-IFN/RBV therapy (Fig. 3b).
Amino acid residues of aa 70 and 91 were conserved irrespective of
differences in the PEG-IFN/RBV responses. On the other hand,
although amino acid variations were also sometimes found at
residues 4 and 110 in genotype 2b HCV, their frequency was low,
and no evident association between the variation and the treatment
response was found. Although the reason of the lack of association
between the Core and the PEG-IFN/RBV treatment response in
genotype-2b HCV infection is unknown, it suggests that a different
mechanism affecting the treatment response might exist, depending
on genotype-specific viral features.
In genotype 1 HCV, variations within the PKR-binding region
of NS5A, including those within the ISDR, were reported to
disrupt the NS5A-PKR interaction, possibly rendering HCV
sensitive to the antiviral effects of interferon [25]. Clinically, the
number of substitutions within the ISDR has been reported to
correlate with the serum HCV RNA level in genotype 1 and 2a
infections [13]. In addition, a recent study reported that mutations
in the ISDR also show the correlation with the relapse in the PEG-
IFN/RBV therapy in genotype 1b infection [26]. Because NS5A
aa2224–2242, part of ISDR, was extracted as one of those regions
related to the treatment response in genotype 2b infection, we
undertook further analysis to investigate the correlation between
amino acid variation numbers and serum HCV RNA level.
Though the reason is unknown, we could not find evidence of a
relationship between variation in the NS5A aa 2224–2242 and
HCV RNA titer in genotype 2b infection, unlike genotypes 1 and
2a. Of note, a high SVR rate in genotype1 and genotype 2a
infection is known to be closely correlated with a low HCV RNA
level and multiple substitutions in ISDR. However, in genotype 2b
infection in our study, there was no significant difference in the
HCV RNA level between SVR and non-SVR patients, as shown
in Table 1. Previously, the role of the ISDR in the contribution to
SVR in genotype 1 and 2a has been discussed in detail in the
context of serum HCV RNA level, and multiple substitutions in
the ISDR are related to a low HCV RNA level and high SVR
rate. However, it is not known which of these two factors is directly
associated with viral clearance. Consideration of this three-sided
relationship of ISDR, HCV RNA level and SVR rate in genotype-
2b infection leads to the suggestion that amino acid variation in
ISDR to be more direct contributor for SVR.
In spite of these findings, there were still limitations in our study.
First, because genotype 2b infection only accounts for 10% of all
HCV infection in Japan, the number of studied patients was rather
small, especially non-SVR patients. In addition, because genotype
2b HCV contains as many as 3033 amino acids, it is possible that
incorrect amino acids or regions were judged as significant in the
complete HCV ORF comparison study as a result of type I errors.
Therefore, if more patients were available for the analysis, the
statistical power detecting the meaningful differences would be
greater. Secondly, we could not include the IL28B SNP analysis in
this study. If we could have combined the information of IL28B
SNPs with the full HCV ORF information, a more comprehensive
analysis would have been achieved.
In conclusion, we have shown that viral sequences were more
diverse in SVR patients infected with genotype 2b HCV. Through
systematic comparison between SVR and non-SVR patients, we
have also shown that several localized regions were extracted as hot
spots whose amino acid substitutions were closely related to the final
outcome by affecting the relapse rate in the PEG-IFN/RBV therapy.
Supporting Information
Table S1 GenBank Accession Numbers. Obtained Gen-
Bank accession numbers for 60 genotype-2b HCV full open
reading frame sequences are listed.
(DOC)
Table S2 Substitutions in NS5A aa 2224–2242 Amino
Acid Regions and SVR rate. SVR rate increased with the
number of substitutions in this region.
(DOC)
Table S3 Substitutions in NS5A aa 2379–2405 Amino
Acid Regions and SVR rate. SVR rate increased with the
number of substitutions in this region.
(DOC)
Table S4 Substitutions in NS2 aa 879–893 Amino Acid
Regions and SVR rate. SVR rate increased with the number of
substitutions in this region.
(DOC)
Table S5 Substitutions in E2 aa 723–770 Amino Acid
Regions and SVR rate. SVR rate increased with the number of
substitutions in this region.
(DOC)
Table S6 PCR Primer List. Primers designed to perform two-
step nested PCR for this study are listed. Dominant genotype-2b
HCV full open reading frame sequences was determined by the 24
partially overlapping amplicons amplified by these primers.
(XLS)
Acknowledgments
We are grateful to Yamanashi Pegintron Ribavirin Study Group and
Ochanomizu Liver Conference Group for their cooperation and advice.
Especially, we thank Asuka Kanayama and Takako Ohmori for their
technical assistance, and Takatoshi Kitamura and Shunichi Okada for
their cooperation and advice.
Author Contributions
Conceived and designed the experiments: MK SM NE. Performed the
experiments: MK. Analyzed the data: MK SM NE. Contributed reagents/
materials/analysis tools: RS MM HS KK. Wrote the paper: MK SM NE.
Critical revision of the manuscript for important intellectual content: FA
TU TI MS MN NS MW.
References
1. Ghany MG, Strader DB, Thomas DL, Seeff LB (2009) Diagnosis, management,
and treatment of hepatitis C: an update. Hepatology 49: 1335–1374.
2. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, et al.
(1989) Recombinant interferon alfa therapy for chronic hepatitis C. A randomized,
double-blind, placebo-controlled trial. N Engl J Med 321: 1506–1510.
3. Haydon GH, Jarvis LM, Blair CS, Simmonds P, Harrison DJ, et al. (1998)
Clinical significance of intrahepatic hepatitis C virus levels in patients with
chronic HCV infection. Gut 42: 570–575.
4. Simmonds P (1997) Clinical relevance of hepatitis C virus genotypes. Gut 40:
291–293.
HCV2b Sequences and PEG-IFN/RBV Response
PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e245145. Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, et al. (2004)
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C:
a randomized study of treatment duration and ribavirin dose. Ann Intern Med
140: 346–355.
6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al.
(2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus
ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet
358: 958–965.
7. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic
variation in IL28B predicts hepatitis C treatment-induced viral clearance.
Nature 461: 399–401.
8. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009)
Genome-wide association of IL28B with response to pegylated interferon-alpha
and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105–1109.
9. Rauch A, Kutalik Z, Descombes P, Cai T, di Iulio J, et al. (2010) Genetic
variation in IL28B Is Associated with Chronic Hepatitis C and Treatment
Failure - A Genome-Wide Association Study. Gastroenterology.
10. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, et al. (1996)
Mutations in the nonstructural protein 5A gene and response to interferon in
patients with chronic hepatitis C virus 1b infection. N Engl J Med 334: 77–81.
11. El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, et al. (2008)
Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical
outcome of pegylated interferon/ribavirin combination therapy. Hepatology 48:
38–47.
12. Hamano K, Sakamoto N, Enomoto N, Izumi N, Asahina Y, et al. (2005)
Mutations in the NS5B region of the hepatitis C virus genome correlate with
clinical outcomes of interferon-alpha plus ribavirin combination therapy.
J Gastroenterol Hepatol 20: 1401–1409.
13. Chayama K, Suzuki F, Tsubota A, Kobayashi M, Arase Y, et al. (2000)
Association of amino acid sequence in the PKR-eIF2 phosphorylation homology
domain and response to interferon therapy. Hepatology 32: 1138–1144.
14. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, et al. (2005) Association of
amino acid substitution pattern in core protein of hepatitis C virus genotype 1b
high viral load and non-virological response to interferon-ribavirin combination
therapy. Intervirology 48: 372–380.
15. Duverlie G, Khorsi H, Castelain S, Jaillon O, Izopet J, et al. (1998) Sequence
analysis of the NS5A protein of European hepatitis C virus 1b isolates and
relation to interferon sensitivity. J Gen Virol 79(Pt 6): 1373–1381.
16. Hofgartner WT, Polyak SJ, Sullivan DG, Carithers RL, Jr., Gretch DR (1997)
Mutations in the NS5A gene of hepatitis C virus in North American patients
infected with HCV genotype 1a or 1b. J Med Virol 53: 118–126.
17. Zeuzem S, Lee JH, Roth WK (1997) Mutations in the nonstructural 5A gene of
European hepatitis C virus isolates and response to interferon alfa. Hepatology
25: 740–744.
18. Donlin MJ, Cannon NA, Aurora R, Li J, Wahed AS, et al. (2010) Contribution
of genome-wide HCV genetic differences to outcome of interferon-based
therapy in Caucasian American and African American patients. PLoS One 5:
e9032.
19. Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, et al. (2007) Pretreatment
sequence diversity differences in the full-length hepatitis C virus open reading
frame correlate with early response to therapy. J Virol 81: 8211–8224.
20. Kobayashi M, Watanabe K, Ishigami M, Murase K, Ito H, et al. (2002) Amino
acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes
2a and 2b and its relation to viral load and response to interferon.
Am J Gastroenterol 97: 988–998.
21. Murakami T, Enomoto N, Kurosaki M, Izumi N, Marumo F, et al. (1999)
Mutations in nonstructural protein 5A gene and response to interferon in
hepatitis C virus genotype 2 infection. Hepatology 30: 1045–1053.
22. Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, et al. (2011) Analysis
of the complete open reading frame of hepatitis C virus in genotype 2a infection
reveals critical sites influencing the response to peginterferon and ribavirin
therapy. Hepatol Int.In Press.
23. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, et al. (2009)
Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C
Virus Genotype 2a High Viral Load and Virological Response to Interferon-
Ribavirin Combination Therapy. Intervirology 52: 301–309.
24. Hayashi K, Katano Y, Honda T, Ishigami M, Itoh A, et al. (2009) Mutations in
the interferon sensitivity-determining region of hepatitis C virus genotype 2a
correlate with response to pegylated-interferon-alpha 2a monotherapy. J Med
Virol 81: 459–466.
25. Gale M, Jr., Blakely CM, Kwieciszewski B, Tan SL, Dossett M, et al. (1998)
Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein:
molecular mechanisms of kinase regulation. Mol Cell Biol 18: 5208–5218.
26. Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, et al. (2010) Pre-
treatment prediction of response to pegylated-interferon plus ribavirin for
chronic hepatitis C using genetic polymorphism in IL28B and viral factors.
J Hepatol.
HCV2b Sequences and PEG-IFN/RBV Response
PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e24514